Diagnos Laboratorium Utama PT Tbk

The company's capital structure is characterized by a debt-to-equity ratio of 0.35, indicating a relatively conservative leverage position. However, the free cash flow is negative at -507,019,330 IDR, suggesting that the company is currently spending more on capital expenditures than it is generating in operating cash flow. The liquidity position is assessed as medium, with a current ratio of 3.37, which is above the typical threshold for financial stability.

Profitability metrics show a return on equity of 0.48% and a return on assets of 0.32%, which are below the industry median for healthcare facilities and services. The company reported a net income of 940,044,360 IDR despite an operating loss of -168,921,280 IDR, indicating that non-operating income or gains may be contributing to profitability.

The company's revenue is concentrated in its core diagnostic laboratory services, with no disclosed geographic diversification. The financial snapshot does not provide segment-specific revenue data, making it difficult to assess the contribution of different service lines or geographic regions to overall performance.

Looking at the growth trajectory, the company's capital expenditures were -16,249,706,180 IDR, which is a significant outlay. The negative free cash flow suggests that the company is investing heavily in its operations, potentially to expand capacity or improve service offerings. However, the operating cash flow of 11,834,139,300 IDR indicates that the company is still generating positive cash from operations.

The risk assessment highlights a medium liquidity risk, with a current ratio of 3.37, and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company's cash reserves are insufficient to cover its long-term debt obligations, which could pose a liquidity challenge in the future.

Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The financial data indicates a focus on capital expenditures, but there is no mention of new product launches, market expansion, or significant regulatory changes that could impact the company's performance.

Net income surged 293% year-over-year to IDR 2.9 billion, signaling a strong operational turnaround and profitability recovery.

Free cash flow turned positive to IDR 5.6 billion, marking a 119.4% improvement and demonstrating enhanced cash generation capabilities.

Cash conversion ratio of 12.59 ranks as best-in-class within the healthcare cohort, indicating superior efficiency in generating cash from earnings.

Long-term debt decreased significantly to IDR 86 billion, reducing leverage and strengthening the balance sheet compared to previous periods.

Operating income expanded by 525.9% year-over-year, highlighting a substantial improvement in core operational profitability margins.

Revenue CAGR of -13.8% over four years indicates a persistent long-term decline in top-line growth momentum.

Return on equity of 0.48% is significantly below the cohort median of 4.56%, reflecting poor capital efficiency for shareholders.

Net margin of 2.39% trails the healthcare sector median of 4.15%, indicating lower overall profitability compared to industry standards.